Drug Profile
Research programme: Huntington's disease therapeutics - CHDI/Roche
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CHDI; Trophos
- Developer CHDI; Roche
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease